Matthew Fowler


Deep Responses Yielded With Daratumumab Plus CyBorD Followed by Daratumumab Maintenance in Multiple Myeloma

June 14th 2021

For patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status, daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses.

Cilta-Cel Elicits Improved Outcomes in Relapsed/Refractory Myeloma Vs Conventional Therapy

June 11th 2021

Patients with relapsed/refractory multiple myeloma who were treated with ciltacabtagene autoleucel experienced improved outcomes over those who received a conventional therapy

Cilta-cel Yields Survival Benefit vs Standard Treatment in Triple–Relapsed/Refractory Multiple Myeloma

June 11th 2021

Ciltacabtagene autoleucel demonstrated efficacious responses and significant improvements in survival over standard of care in triple class–relapsed/refractory multiple myeloma.

Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups

June 9th 2021

The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.

First-Line Ibrutinib/Venetoclax Inhibits Response in CLL/SLL

June 7th 2021

Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

First-Line Ibrutinib Yields 7-Year Survival Benefit in CLL

June 5th 2021

Single-agent ibrutinib given in the first-line setting sustained a progression-free survival and overall survival benefit compared with chlorambucil as therapy for patients with chronic lymphocytic leukemia at 7-year follow-up.

Adavosertib/Irinotecan Shows Early Activity in Pediatric Neuroblastoma

April 12th 2021

Adavosertib plus irinotecan showed early activity in a cohort of pediatric patients with neuroblastoma, thus meeting the protocol-defined efficacy end point of the 1/2 ADVL1312 trial.

Nivolumab/Ipilimumab Showcases Significant Antitumor Activity in Metastatic CRPC

April 10th 2021

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.

Neoadjuvant Nivolumab/Chemo Improves pCR in Resectable NSCLC

April 10th 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

JSP191 With Low-Dose Irradiation and Fludarabine Shows Promise in MRD+ AML/MDS

February 9th 2021

February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.